Mostrar el registro sencillo del ítem

dc.contributor.authorBellido-Estevez, Inmaculada 
dc.contributor.authorLopez, C
dc.contributor.authorBellido, M Victoria
dc.contributor.authorBlanco-Reina, Encarnacion 
dc.contributor.authorGómez-Luque, A.
dc.date.accessioned2015-04-13T07:54:41Z
dc.date.available2015-04-13T07:54:41Z
dc.date.created2015
dc.date.issued2015-04-13
dc.identifier.urihttp://hdl.handle.net/10630/9643
dc.descriptioneposteres_ES
dc.description.abstractWe aim to determine risk and protective factors influencing relapse incidence in outpatient with schizophrenia. A longitudinal, observational study was done with outpatients with schizophrenia (F20) or schizoaffective disorder (F25)(DMS-IV and ICD-10), without hospitalization during the previous 6 months. The patients were consecutively included into the study to received oral (O-A) or long-acting injectable (depot-A) antipsychotics. Clinical stage evolution, compliance, efficacy and safety assessments (including PANSS, CGI-SSI, hospitalization rates, and adverse events) were recorded before and after 6 and 12 months of treatment. Results: 60 outpatients (aged 34.5±8.9, male 73%), 75% schizophrenia and 25% schizoaffective disorder diagnosis, 68.3% fewer than 15 years of schizophrenia evolution, 76.7% fewer than 5 times previous hospitalizations were treated with O-A (41.7%) or depot-A (58.3%) antipsychotics for at least one year. Depot-A treated patients showed a significant higher compliance compared to O-A patients during the all following time, lower PANSS (total, positive and negative) scores and CGI-SSI score (p<0.01), and a delayed relapse incidence and re-hospitalization to more than 1 year in the 48% of patients (relapse % depot/% oral) after 6 months 22.9%/52.0%, and after 12 months 48.6%/4.0%. Conclusion: There were protective factors which delayed relapse incidence in schizophrenia: Use of sustained-release preparations, family support. There were risk factors for occurrence of relapse in schizophrenia: cocaine, heroin and alcohol consumption, absence of family support, greater severity of patients assessed through CGI-SI, male sex, age older than 25 years and long-term evolution of the disorder.es_ES
dc.description.sponsorshipUniversidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectEsquizofreniaes_ES
dc.subject.otherRelapsees_ES
dc.subject.otherSchizophreniaes_ES
dc.subject.otherRisk factorses_ES
dc.subject.otherProtective factorses_ES
dc.titleRisk and protective factors for release in outpatients with schizophreniaes_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Medicinaes_ES
dc.relation.eventtitle23th European Congress of Psychiatry (EPA-2015).es_ES
dc.relation.eventplaceVienna, Austriaes_ES
dc.relation.eventdate28 de Marzo, 2015es_ES
dc.identifier.orcidhttps://orcid.org/0000-0002-9362-8635es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem